Medium term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea

Gut

Volumn 42, Issue 5, 1998, Pages 628-634

  Saslow, S B ^a   Scolapio, J S ^a   Camilleri, M ^a   Forstrom, L A ^a   Thomforde, G M ^a   Burton, D D ^a   Rubin, J ^a   Pitot, H C ^a   Zinsmeister, A R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alosetron; Antagonist; Carcinoid diarrhoea; Colonic transit; Serotoninergic agents

Indexed keywords

ALOSETRON;

ADULT; AGED; ARTICLE; CARCINOID; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; FEMALE; HUMAN; INTESTINE CARCINOMA; INTESTINE CONTRACTION; INTESTINE MOTILITY; MALE; PRIORITY JOURNAL;

EID: 0031839310     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.42.5.628     Document Type: Article

References (32)

1. Feldman JM, Plonk JW. Gastrointestinal and metabolic function in patients with the carcinoid syndrome. Am J Med Sci 1977;273:43-54.
2. Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1503-22.
3. Donowitz M, Binder HJ. Jejunal fluid and electrolyte secretion in carcinoid syndrome. Dig Dis 1975;20:1115-22.
4. von der Ohe M, Camilleri M, Kvols LK, et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhoea. N Engl J Med 1993; 329:1073-8.
5. Feldman JM, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986;81:41-8.
6. Emson PC, Gilbert RFT, Martensson H, et al. Elevated concentrations of substance P and 5-HT in plasma in patients with carcinoid tumors. Cancer 1984;54:715-8.
7. von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 1994;35:536-41.
8. 3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhoea. Gastroenterology 1994;106:1184-9.
9. Schworer H, Munke H, Stockmann F, et al. Treatment of diarrhoea in carcinoid syndrome with ondansetron, tropisetron, and clonidine. Am J Gastroenterol 1995;90:645-8.
10. 3) receptor antagonist ICS205 930 in the carcinoid syndrome. Aliment Pharmacol Ther 1998;2:167-72.
11. Platt AJ, Heddle RM, Rake MO, et al. Ondansetron in carcinoid syndrome [letter]. Lancet 1992;339:1416.
12. Buhl C, Fibbe C, Frenzel H. Ondansetron in carcinoid syndrome. Dtsch Med Wochenschr 1992;117:1821.
13. Alosetron: clinical investigators' brochure. Glaxo Wellcome Pharmaceuticals Research and Development, 1995.
14. Rudd JA, Naylor RJ. Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 1994;33:1607-8.
15. Zerbib F, Bruley des Varannes S, Oriola RC, et al. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994;8:403-7.
16. Bardhan K, Bodemar G, Geldof H, et al. A double-blind, placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome [abstract]. Gastroenterology 1996;110:A630.
17. Delvaux M, Louvel D, Mamet JP. Effect of alosetron on colonic sensitivity in patients with irritable bowel syndrome [abstract]. Gastroenterology 1996;110:A655.
18. 3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990;35:477-80.
19. Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992;67:732-8.
20. Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989;257:G284-90.
21. Proano M, Camilleri M, Phillips SF, et al. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990;258:G856-62.
22. Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992;103:36-42.
23. Camilleri M, Zinsmeister AR, Greydanus MP, et al. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991;36:609-15.
24. Tietz NW. Textbook of clinical chemistry. 1st edn. Philadelphia: Saunders, 1986.
25. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663-6.
26. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
27. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte α interferon. J Clin Oncol 1989;7: 865-8.
28. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994;35: S1-4.
29. Nelson-Piercy C, Hammond PJ, Gwilliam ME, et al. Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects. J Clin Endocrinol Metab 1994;78:329-36.
30. Priou A, Levesque G, Simonetta C, et al. Long acting sandostatin in the treatment of acromegaly. Ann Endocrinol 1995;56:213-18.
31. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991;67:33-6.
32. Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990;35: 477-80.